Sam Brusco, Associate Editor07.28.22
Neurovascular device maker Rapid Medical has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions.
According to the company, TIGERTRIEVER 13 is the smallest revascularization device to date. It removes thrombus from delicate blood vessels during an ischemic stroke, and is the only device that adjusts to the vasculature and clot, which is more atraumatic.
“The neurovascular field has been waiting for a thrombectomy device dedicated to small vessels,” Dr. David Fiorella of Stony Brook University Medical Center told the press. “Medical therapy is currently suboptimal for these patients, so there can be a huge benefit for devices that emergently restore blood flow while minimizing the potential for harm.”
TIGERTRIEVER’s adjustability is a result off complex 3D braiding, borrowing from recent aerospace engineering advances. It is precisely controlled to capture the clot and remove tension from the vasculature prior to removal. It touts the lowest profile of any stent retriever, according to the company—24% smaller than 3mm devices.
“Thousands of procedures have already been performed with TIGERTRIEVER 13 worldwide,” describes James Romero, president, Americas, of Rapid Medical. “Now U.S. physicians finally have access to TIGERTRIEVER 13’s unique capabilities to further benefit patients suffering from ischemic stroke.”
The company began enrollment for its DISTALS study, an IDE trial to assess mechanical thrombectomy in distal stroke, earlier this month.
According to the company, TIGERTRIEVER 13 is the smallest revascularization device to date. It removes thrombus from delicate blood vessels during an ischemic stroke, and is the only device that adjusts to the vasculature and clot, which is more atraumatic.
“The neurovascular field has been waiting for a thrombectomy device dedicated to small vessels,” Dr. David Fiorella of Stony Brook University Medical Center told the press. “Medical therapy is currently suboptimal for these patients, so there can be a huge benefit for devices that emergently restore blood flow while minimizing the potential for harm.”
TIGERTRIEVER’s adjustability is a result off complex 3D braiding, borrowing from recent aerospace engineering advances. It is precisely controlled to capture the clot and remove tension from the vasculature prior to removal. It touts the lowest profile of any stent retriever, according to the company—24% smaller than 3mm devices.
“Thousands of procedures have already been performed with TIGERTRIEVER 13 worldwide,” describes James Romero, president, Americas, of Rapid Medical. “Now U.S. physicians finally have access to TIGERTRIEVER 13’s unique capabilities to further benefit patients suffering from ischemic stroke.”
The company began enrollment for its DISTALS study, an IDE trial to assess mechanical thrombectomy in distal stroke, earlier this month.